Sfoglia per AUTORE
SCHECTER J
Collezione AOU Città della Salute di Torino
Items : 2
Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial. in The Lancet. Haematology / Lancet Haematol. 2025 Jan;12(1):e45-e56. doi: 10.1016/S2352-3026(24)00320-X.
2025
AOU Città della Salute di Torino
AOU Città della Salute di Torino
Mina R; Mylin AK; Yokoyama H; Magen H; Alsdorf W; Minnema MC; Shune L; Isufi I; Harrison SJ; Shah UA; Schecter JM; Vogel M; Lendvai N; Gries KS; Katz EG; Slaughter A; Lonardi C; Gilbert J; Li Q; Deraedt W; Filho OC; Patel N; Florendo E; Karlin L; Weisel K;
Minimal Residual Disease-Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized Trials. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2025 Feb 12:JCO2402020. doi: 10.1200/JCO-24-02020.
2025
AOU Città della Salute di Torino
AOU Città della Salute di Torino
Shi Q; Paiva B; Pederson LD; Dimier N; Talpes E; Prior TJ; Orfao A; Moreau P; Sonneveld P; Kumar SK; Dixon JG; Patel R; Bartlett BJ; Schecter J; McCarthy P; Hose D; Seckinger A; Mattia D; Goldschmidt H; Oliva S; Owen RG; Anderson KC; San-Miguel J; Durie BGM; Munshi N;